Literature DB >> 21549596

Structure-activity relationship of cyclic thiacarbocyanine tau aggregation inhibitors.

Kelsey N Schafer1, Dhiraj P Murale, Kibong Kim, Katryna Cisek, Jeff Kuret, David G Churchill.   

Abstract

Macrocyclic bis-thiacarbocyanines are efficacious inhibitors of tau protein aggregation. To extend the structure-activity relationship of this inhibitor class, N,N'-alkylene bis-thiacarbocyanines linked by chains of three to eight methylene carbons were synthesized and examined for inhibitory activity against recombinant human tau aggregation in vitro. At 10 micromolar concentration, inhibitory activity varied with linker length, with four methylene units being most efficacious. On the basis of absorbance spectroscopy measurements, linker length also affected compound folding and aggregation propensity, with a linker length of four methylene units being optimal for preserving open monomer conformation. These data suggest that inhibitory potency can be optimized through control of linker length, and that a contributory mechanism involves modulation of compound folding and aggregation.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21549596      PMCID: PMC4291179          DOI: 10.1016/j.bmcl.2011.04.039

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

1.  Electron microscopy as a quantitative method for investigating tau fibrillization.

Authors:  Mihaela Necula; Jeff Kuret
Journal:  Anal Biochem       Date:  2004-06-15       Impact factor: 3.365

2.  Ligand-dependent inhibition and reversal of tau filament formation.

Authors:  Carmen Chirita; Mihaela Necula; Jeff Kuret
Journal:  Biochemistry       Date:  2004-03-16       Impact factor: 3.162

3.  Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins.

Authors:  Sayuri Taniguchi; Nobuyuki Suzuki; Masami Masuda; Shin-ichi Hisanaga; Takeshi Iwatsubo; Michel Goedert; Masato Hasegawa
Journal:  J Biol Chem       Date:  2004-12-17       Impact factor: 5.157

4.  Rhodanine-based tau aggregation inhibitors in cell models of tauopathy.

Authors:  Bruno Bulic; Marcus Pickhardt; Inna Khlistunova; Jacek Biernat; Eva-Maria Mandelkow; Eckhard Mandelkow; Herbert Waldmann
Journal:  Angew Chem Int Ed Engl       Date:  2007       Impact factor: 15.336

Review 5.  Biochemistry of Tau in Alzheimer's disease and related neurological disorders.

Authors:  Nicolas Sergeant; Alexis Bretteville; Malika Hamdane; Marie-Laure Caillet-Boudin; Pierre Grognet; Stephanie Bombois; David Blum; André Delacourte; Florence Pasquier; Eugeen Vanmechelen; Susanna Schraen-Maschke; Luc Buée
Journal:  Expert Rev Proteomics       Date:  2008-04       Impact factor: 3.940

6.  Potent inhibition of scrapie prion replication in cultured cells by bis-acridines.

Authors:  Barnaby C H May; Aaron T Fafarman; Septima B Hong; Michael Rogers; Leslie W Deady; Stanley B Prusiner; Fred E Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

7.  Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation.

Authors:  Carlo Ballatore; Kurt R Brunden; Francesco Piscitelli; Michael J James; Alex Crowe; Yuemang Yao; Edward Hyde; John Q Trojanowski; Virginia M-Y Lee; Amos B Smith
Journal:  J Med Chem       Date:  2010-05-13       Impact factor: 7.446

8.  Anionic micelles and vesicles induce tau fibrillization in vitro.

Authors:  Carmen N Chirita; Mihaela Necula; Jeff Kuret
Journal:  J Biol Chem       Date:  2003-05-01       Impact factor: 5.157

9.  Potent inhibition of tau fibrillization with a multivalent ligand.

Authors:  Nicolette S Honson; Jordan R Jensen; Michael V Darby; Jeff Kuret
Journal:  Biochem Biophys Res Commun       Date:  2007-09-06       Impact factor: 3.575

10.  Structure-activity relationship of cyanine tau aggregation inhibitors.

Authors:  Edward Chang; Erin E Congdon; Nicolette S Honson; Karen E Duff; Jeff Kuret
Journal:  J Med Chem       Date:  2009-06-11       Impact factor: 7.446

View more
  3 in total

1.  Structural determinants of Tau aggregation inhibitor potency.

Authors:  Kelsey N Schafer; Katryna Cisek; Carol J Huseby; Edward Chang; Jeff Kuret
Journal:  J Biol Chem       Date:  2013-09-26       Impact factor: 5.157

2.  Sulfur-containing therapeutics in the treatment of Alzheimer's disease.

Authors:  Haizhou Zhu; Venkateshwara Dronamraju; Wei Xie; Swati S More
Journal:  Med Chem Res       Date:  2021-01-15       Impact factor: 1.965

Review 3.  Potential synergy between tau aggregation inhibitors and tau chaperone modulators.

Authors:  Laura J Blair; Bo Zhang; Chad A Dickey
Journal:  Alzheimers Res Ther       Date:  2013-09-16       Impact factor: 6.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.